Patent Application
20090156975
The present invention relates to the field of accessing blood, and more specifically to methods and apparatuses that remove blood from a patient for treatment or analysis and return at least a portion of the blood to the patient.
In recent years, the frequent monitoring of blood parameters has become much more common. For example blood glucose is commonly monitored for the implementation of tight glycemic control protocols, and lactate is monitored for the general perfusion assessment. The adoption of care practices that require frequent blood monitoring have necessitated the development of systems that enable blood to be obtained on a regular basis.
In general terms such a blood access system is capable of removing blood from the patient and presenting the blood to a measurement and/or processing system. The measurement system can comprise various measurement technologies, including without limitation ion specific electrodes, optical measurements, plasma separation techniques, ultra filtration, etc. Occlusions in such blood access systems can lead to undesirable outcomes, so it can be important that the system be able to determine when an occlusion has occurred such that a care provider can assess and manage the situation. In addition to the loss of measurement information, rapid detection of occlusions is important since stagnant blood in the blood access system can clot over time and the access site can be lost for future measurements.
Via Medical developed a blood access system that withdrew blood from the body for measurement of glucose and other parameters by ion specific electrodes. The system detected occlusion by having an allowable time for procurement of the sample. The system knew the start time of the withdrawal and was able to sense the arrival of the blood. If the blood did not arrive within a fixed period of time then the system would alarm.
CHF Solutions has developed a system for ultra filtration that uses pressure thresholds for determination of an occlusion. The system is based upon a pressure measurement made on the access line used for blood removal and a second pressure measurement used on the infusion line. The system has two thresholds that are used for the determination of an occlusion.
Current blood access systems do not provide an ability to monitor or assess the patency (or viability) of the blood access site. Current systems generally operate until an occlusion occurs, trigger an alarm, and then stop operations until medical personnel clear the occlusion. Although existing blood access systems do not evaluate site patency, medical personnel routinely desire to evaluate the patency of a blood access site.
Medical personnel manually determine the viability of an access site by drawing and infusing blood and/or saline through the catheter using a syringe. They perform this check both at the time of catheter insertion and at later times when the patency of the site is in question. Equally importantly, medical personnel clear small occlusion from within catheters by generating high pressure/high rate flows using a syringe directly attached to the catheter. The pressure and flows generated by medical personnel frequently exceed the safe limits that automated systems are allowed to generate. Blood access systems typically operate in one of two fundamental modes: flow control or pressure control. During flow control, the pumping system is targeting a predetermined flow rate and uses the pumping system generates whatever pressure is required to reach this flow target. For safety, the maximum infusion pressure and minimum withdrawal pressure are normally limited. If the system reaches either of these limits during pumping operations, an occlusion is declared and pumping stops. When a blood access system operates in pressure control mode, the pumps turn at whatever rate is required to reach a predetermined pressure value. The pressure value is selected to achieve withdrawal or infusion during a pumping operation. If the desired volume of fluid is not pumped during a preset period of time, the system declares an occlusion and stops pumping.
However, existing blood access systems still do not provide sufficiently robust operation to operate with the reliability desired, such as predicting and avoiding occlusions and/or bubbles, managing occlusions and/or bubbles if they occur, automatic cleaning of the blood access system, and determining and managing the patency of the blood access site.
Embodiments of the present invention provide robust systems for the removal and subsequent infusion of blood for measurement purposes, and embodiments of the present invention provide methods of operating such systems and providing capabilities such as predicting and avoiding occlusions and/or bubbles, managing occlusions and/or bubbles if they occur, automatic cleaning of the blood access system, and determining and managing the patency of the blood access site. Such operational challenges can occur during any of several phases of operation of a blood access system. Embodiments of the present invention can effectively incorporate a variety of inputs for the identification of trends consistent with present or pending occlusions. An embodiment of the present invention can be aware of the stage of operation, e.g., withdrawal, infusion, or cleaning, and the prior performance of the system. Embodiments of the present invention can have the ability to identify the location of the problem so that effective procedures can be used to resolve the problem. The following description first describes aspects of the present invention in the context of a particular class of blood access system and particular measurement technology. The invention is not necessarily limited to that class of blood access system or that type of measurement technology; descriptions of other types of blood access systems that are suitable for use with the present invention are also provided. Also, the invention is not necessarily limited to systems incorporating all of the features or elements described herein; subsets of the features and elements can provide useful systems for many applications, and can be incorporated into other systems to improve the performance of such other systems.
In the operation of a blood access system, operational stoppages or disruptions can result from one or more of the following:
Embodiments of the present invention can use some or all of the following information for detection and management of occlusions and/or air bubbles (and to provide other features and capabilities as described elsewhere herein):
In addition to occlusions, embodiments of the present invention also can recognize an air bubble in the line and prevent infusion. The effective detection and subsequent management of air bubbles can facilitate reliable operation of a blood access system. Air bubbles can occur due to out gassing of saline when subjected to negative pressure, from a variety of connection points, and from a priming sequence. It can be desirable for the system to detect the bubble, clear the bubble and resume normal operation.
Dilution of the Blood Sample
For descriptive purposes, consider that the sensor set is completely primed with a maintenance fluid, such as saline, to effect non-compliant movement of the blood. As the blood is drawn from the patient through the tubing, the blood—saline interface becomes smeared by laminar flow effects and mixing. The size of this interface between undiluted blood and saline becomes larger as the draw continues. Since many glucose measurement systems cannot tolerate significant dilution, blood can be drawn past the glucose sensor and collected in a tubing reservoir until an undiluted blood sample is presented at the sensor.
Minimization of Blood Loss and Fluids Infusion
The example blood access system provides a balance so that blood loss is minimized while fluid overload of the patient does not occur. In general terms the limit of fluid infusion can be set at approximately 10% of a typical fluid maintenance rate. This involves a careful determination of infused volume to compensate for blood-saline mixing, and the use of specific fluid flow rates and patterns that facilitate cleaning of the conduit during the phases of blood infusion and cleaning. With respect to blood loss, the general desire is to minimize blood loss to the extent possible.
Maintenance of Patency and Minimization of Cellular Aggregation
Extracorporeal blood tends to adhere to foreign surfaces and over a period of a few minutes solidifies. Treating with anticoagulants can reduce this tendency, but can be incompatible with reinfusion into the patient. An automated blood access system that conserves blood, and maintains patency through the catheter, can operate such that the processes of drawing, measurement, and infusion can be completed within a time frame that prevents damage to the blood and excessive aggregation of blood within the walls of the tubing, sensor and catheter. The time at which these components are allowed to be exposed to drawn blood is referred to as the residence time.
To further maintain patency, remaining traces of blood, left after infusion, can be flushed from the sensor set using maintenance fluids.
Description of Hardware Components
An example blood access system can be described in the context of three component groups, (1) a console, (2) a disposable cassette and circuit and (3) fluid bags that attach to the circuit. Additional information regarding system components is described below (see associated figures for additional information).
Console
Pumps. Pumps provide the ability to move blood and maintenance fluids (typically normal saline) between the patient and the optical sensor. The pumps can be, for example, standard peristaltic pumps which enable bi-directional flow and support stop flow conditions. The example system has two pumps, denoted the blood pump and the flush pump.
Control System. Algorithms that control the pump speeds and directions and measure the sensor set pressures to achieve a complete normal blood access cycle. The normal cycle 1) maintains patency between blood samples 2) withdraws a blood sample 3) returns the blood sample and 4) cleans the sensor set. The control system also provides fluid motion for priming the sensor set as well as detecting fault events in the blood access cycle and can exercise automated procedures to clear the faults, or where not possible, alert the user.
Disposable Cassette and Circuit
Circuit Tubing. The circuit tubing provides for the fluid pathways, including the pump loop tubing and conduits that convey blood and maintenance fluid between the patient and optical sensor. Additional tubing provides for a flush line which provides an effective mechanism for cleaning. The circuit tubing also includes a number of one-way valves that prevent infusion of contaminated saline.
Pressure Sensors. Two pressure sensors measure pressures inside the sensor set near the pump loops. There is a blood line pressure sensor and a flush line pressure sensor. Each sensor measures pressures on the patient side of the pump loops.
Cuvette. A cuvette provides an optical window through which an optical glucose sensor operates.
Blood Reservoir. The dilution of blood with saline as it traverses over the long distance of the sample line requires that the actual draw volume exceed the geometric volume of the blood line to make sure that an undiluted sample is presented at the cuvette at the end of the draw. Additional tubing is provided upstream of the cuvette to provide the additional capacity for blood storage, and this tubing can be wound on a form to provide compactness. This coiled tubing is called the blood reservoir.
Bubble detectors. The blood access system can have one or more bubble detectors that sense the presence of bubbles in various locations in the sensor set. A bubble detector can be present at the sensor set T to detect and prevent bubbles from entering the catheter connection line.
Fluid Bags
Source, maintenance fluid. The blood access system can move blood by virtue of an incompressible maintenance fluid, such as saline, present in the conduits of the sensor set. The sensor set accordingly has a connection to a supply of sterile maintenance fluid, such as a bag of saline. The sensor set is configured such that either the blood or flush lines can draw fluid from the maintenance fluid source, but do not allow fluid, once it has entered the set, to return to the maintenance fluid source.
Waste reservoir. The blood access system can provide a means to dispose of maintenance fluids that are used for blood draws and cleaning. A waste reservoir is provided that accepts maintenance fluid and/or trace amounts of blood cleaned from the sensor set. The waste reservoir is connected such that either the blood pump or flush pump can dispose of fluid, but such that fluid, once delivered to waste, cannot reverse into the sensor set.
A sensor set block diagram for the example blood access system as described above is shown in
Automated Blood Access Process
The example blood access system of
Draw Initialization Stage; Clearing Catheter Access
Before the blood draw is started, both the blood and flush pumps are controlled to issue one or more flow pulses at an elevated or maximum flow rate. More than one pulse can be used to insure that at least one pulse will be effective since there is a possibility that the roller may not be fully engaged in the pump race at the start of the pulse. The pulses can clean away any aggregated blood or protein that might have adhered at the catheter tip and any protein sheathing that may have formed during the keep vein open (KVO) stage. To achieve the highest flow rate in the catheter connection line, the pulses in the blood and flush pumps are synchronized. Following each pulse, a delay of about 4 seconds can be used to allow settling of the flow and clearing of the saline that was infused into the vein.
Efficient Blood Withdrawal Stage
The blood pump can be used alone to complete the entire blood draw and measurement. To minimize the total draw time about 80% of the total required blood volume is first drawn at a rapid, variable flow rate. A constant pressure-based draw method can be used to compensate for a varying mix of saline and blood, and to achieve maximum flow rate constrained by a constant upstream pressure that keeps fluid degassing at an acceptable level. As blood replaces saline in the blood line, viscosity and therefore resistance to flow increases so that, for a constant upstream pressure, flow decelerates over time. The termination of this stage of the draw can be determined by calculating the % blood dilution or rate of dilution by use of the optical sensor. An optical sensor can sense both the arrival of blood and the component changes as an undiluted sample becomes present in the optical cell.
Optical Measurement Stage
Following the rapid draw, the pump flow rate can be slowed to a constant flow rate of about 0.5 mL/min to maintain suspension of the red blood cells in plasma during optical measurement, and to allow sufficient time to complete the glucose measurement. If the measurement period is about 90 seconds, an additional 750 mL is withdrawn.
Infusion Stage
After the measurement is completed, infusion begins as a progression of stages that return the blood as quickly as possible to the patient and also begin the process of cleaning the tubing and cuvette. The initial stage of infusion can use pressure-based control which operates at a variable flow rate to maintain upstream pressure at a high constant pressure. This initial stage infuses almost all the blood that was drawn, leaving a remaining saline-blood mixture at the end of the blood line. This rapid infuse stage limits the total time that blood is in the extracorporeal circuit. As an example, the first stage of the infusion can be completed within three minutes.
The next stage of infusion involves a repetitive back and forth motion of the blood pump such that during half of one cycle, the pump pushes blood forward at a constant flow rate and during the second half of the cycle blood is pulled back at about half the rate. Between each forward and backward movement, the pump is briefly held motionless to allow flow to decay to zero. The asymmetric cycle results in a net forward movement of fluid. Since the tubing diameters do not under any operating circumstances permit operation in a turbulent flow regime, the acceleration and deceleration of fluid results in eddies that disrupt the fluid boundary layer which help wash away any cells or other blood products that could potentially adhere to the tubing walls. During this stage of infusion, and if pressure exceeds maximum limits in either direction, the flow is throttled back to limit the pressure. An example commanded flow for this stage of infusion is shown in
Following the 2nd stage of infusion, a 3rd stage begins with the blood pump executing a repetitive forward-pause motion with 50% duty. Although this stage might not be as effective as the forward-reverse flow, it still provides some pulsatile acceleration and washing of blood products from the tubing walls, while providing a higher net forward flow rate per cycle. The flow in this stage is also limited by pressure.
Cleaning Stages
At this point in the cycle, in the example embodiment greater than 97% of the blood has been returned to the patient; the next stages focuses on a more thorough cleaning of the cuvette, tubing and catheter.
‘Scrub’ Stage
The scrub stage involves rapid, reverse-synchronized back and forth motion of the blood and flush pumps so that fluid movement commutes only between the blood and flush lines. Total volume moved per cycle is only about 300 uL and the flow is not turbulent, but the rapid oscillations can create accelerations that lead to eddies that circulate in a cross flow direction and help to wash blood products that collect in the boundary layer and on the walls of the tubing and cuvette to mix with the central stream.
The blood line inside diameter can be sized to minimize the draw time for blood. This diameter optimization takes into account flow resistance, volume, flow velocity, and shear. The flush line on the other hand can be sized at a much larger diameter to provide a conduit for executing high flow rate maneuvers to clean the catheter tip. The relative size difference does not necessarily interfere with any fluid motion functions that require infusion and withdrawal. However, during the Scrub stage, which requires circulation between the lines, and where a zero flow is desired at the catheter, the relative size between the blood and flush lines can create difficulties, especially during transients. Although the blood and flush pumps have identical flow commands, the higher resistance of the blood line slows the actual flow response compared to the flow response in the flush line.
Balancing flow rates in the blood and flush lines can be accomplished by estimating the pressure at the sensor set T junction and using the estimated pressure in feedback to control zero pressure or the expected pressure head at the catheter tip. The process of dynamic balancing results in almost zero flow through the catheter connection line. The result of this control method is illustrated by
Recirculation Stage
Once blood products have been washed into the mainstream by the scrub stage, the blood and flush pumps can be operated at a constant rate such that the bulk of fluid movement occurs from the blood line to the flush line. This washes the remaining blood products in the blood line and flush line towards waste, and filling both legs of the set with clean saline. The blood pump is operated at a slightly higher rate so that a small amount of fluid is driven out through the catheter connection line to hold blood back and to begin cleaning of the extension line and the catheter.
Catheter Flush Stage
The final stage of cleaning the sensor set involves high flow pulses with larger volume pushes to completely clear the catheter connection line, Luer connections and catheter. The blood and flush pumps can be used in synchronization with each other to obtain an effective cleaning flow rate. Delays can be used between the pulses to allow settling of the flow before the next pulse is issued. Since the flush line has the larger inner diameter, the highest flow comes from that line.
Keep Vein Open (KVO) Stage Between Measurements
The system can operate in a KVO stage during the period between measurement cycles. The KVO stage provides a constant flow rate into the patient at a rate that prevents blood from entering the catheter, maintaining an open blood access connection between blood draws.
Frequency of Measurement Cycles
The highest frequency at which measurements can be obtained is limited by the ability to complete the normal sequence of withdraw, measurement, infusion and cleaning stages and a minimal acceptable KVO time. An example system has been developed and tested that supports a measurement frequency of one measurement every 7 minutes.
Exceptional Detection and Management
Occlusions and air bubbles can occur during the operation of a blood access system. Embodiments of blood access systems in accord with the present invention can detect and manage occlusions, restrictions, and air bubbles that occur during operation of the system. These operational problems can occur during any operational phase. As the recovery or management of a given exception is dependent upon the stage or operation, the system can provide different recovery methods depending upon the stage of operation. By the use of two pressure measurements, the system has the ability to identify the location of the problem so that effective procedures or alarms can be provided and allow effective resolution of the problem.
Patency Evaluation.
Embodiments of the present invention can determine the patency of a blood access site using determinations of the actual pressure and flow characteristics of a particular patient and comparing this to an envelop of all pressure flow characteristics determined for an IV configuration and pumping profile. Embodiments of the present invention can determine the patency of a blood access site using comparisons of the actual pressure and flow characteristics of a particular draw of a patient against the historical data of pressure and flow from this patient.
An example embodiment of the present invention uses 8 different techniques to determine the patency of blood access site. A similar 8 techniques can be used for occlusion detection, however the thresholds for occlusion detection can be different than the thresholds of patency evaluation.
There are two elements in the evaluation of the patency of a blood access site with a blood access system operated under flow control:
Flow One: The instantaneous pressure required to push or pull the fluid through the access site at known rates.
Flow Two: The draw to draw evolution of the pressure required to withdraw or infuse fluid into the patient.
There are two elements in the prediction of the patency of a blood access site operated under pressure control:
Pressure One: The minimum sustained flow rate achieved at the desired pressure.
Pressure Two: The evolution of the sustained flow rate from draw to draw.
There are four elements of patency prediction which are common for both pressure and flow based controls:
Use of Pressure and Flow Data.
A blood access system can be programmed to withdraw and infuse at known conditions of pressure and flow. These conditions can be tested in vitro to generate maximum and minimum envelopes of pressure and flow for a particular system. When a new patient is attached to the device, the first blood access event can be compared to these envelopes to make a prediction of the patency of the blood access site. The more data known about the individual patient, the more accurate the patency prediction becomes. In particular, knowledge of the hematacrit of a patient can greatly improve the specificity of the prediction.
The relationship between flow and pressure in many blood access systems can be expressed in a linear equation know as Poiseuille's Equation:
Flow(Q)∝Pressure*(radius of tube)**4/(viscosity*length of tube)
Once the design of a blood access system is complete, the geometric terms in the above relationship are fixed and pressure/flow relationship becomes inversely related to viscosity:
Flow(Q)∝Pressure/viscosity
This simple relationship is at the core of all existing occlusion management systems. To understand the patency evaluation of an access site, the relationship should be rewritten as:
Viscosity∝Pressure/Flow(Q)
The viscosity of a given patient's blood is normally constant and strongly dependent up on hematocrit. An individual patient's blood viscosity can be estimated using the pressure and flow data generated in the blood access system. From draw to draw on a given patient, the estimated viscosity should remain substantially constant and should be in a normal range for humans. Increases in the apparent viscosity are signs of degrading patency. The example system uses algorithms which evaluate the draw to draw evolution of pressure and flow to determine when patency is degrading.
The system can respond to these changes by performing extra cleaning cycles and extra catheter cleaning pulses to re-establish the initial level of patency. If patency cannot be increased by these methods the system alerts the medical personnel of impending failure so they can try to restore blood access prior to actual failure.
The relationships between pressure and flow hold well over all of the normal operating regions for blood access systems, however, the more complicated the system, or the closer to occlusion the system becomes, the worse the estimate of performance using Poiseuille's Equation.
Robustness of Patency Prediction.
The example patency prediction method relies upon two variables which are closely related due to the hemodynamics of the blood access system: the flow and the pressure. A reasonable prediction of patency or impending occlusion benefits from a minimum of two “independent” variables for implementation. An additional element which can make the prediction more robust is the use of trend data generated from a specific patient.
Pumping elements and other non-tubular sections of a blood access system do not always follow Poiseuille's Equation. In vitro test data can be used to hone the limits of the prediction and build robustness into the predictions. Some embodiments of the present invention have elements which can increase the accuracy and specificity of the patency evaluation. In particular, dual pressure sensors connected close to the access site provide a highly accurate measurement of the pressure at the catheter when one of the pumps is stopped. Also optical sensing elements allow a reasonable estimate of hematocrit which allows the prediction to be further enhanced.
Implementation.
Any blood access system which generates known flow rates and contains at least one pressure sensor can implement patency prediction according to the description herein. The accuracy of the thresholds, and the specificity of the prediction can depend on the specific configuration and implementation of the blood access system.
Example Implementation.
Using the example blood access system of
Appropriate blood flow capacity to support the rate of fluid movement.
3.5 mL withdrawn in 30 to 60 seconds
Peak withdraw rates of 15 mL/min
Peak infuse rates of 15 mL/min
Structurally sound to handle associated pumping pressures
Withdraw at down to at −300 mmHg
Infuse at up to +300 mmHg
Not Position sensitive
Catheter not near wall
Catheter not near valve
Site is not Infiltrated
Occlusion Prediction.
A blood conserving blood access system generally requires staged flow operations that 1) draw and transport the blood sample for analysis and 2) infuse the blood back into the patient and 3) clean remaining blood residuals from the system. Aggregation of blood components on the walls of the fluid transporting conduits or clots which can lodge in conduit joints and partially occlude flow can eventually lead to full occlusions of the conduit and failure of the blood access. If the system is able to measure properties within the conduit affected by occlusion, it can predict the onset of these full occluding events, and furthermore the specific location where these events are occurring. This information can be used to warn the caretaker, who subsequently can initiate mitigating actions to restore full patency and avoid failure of the blood access. Alternatively, the system itself can directly use this information and perform automatic maneuvers to mitigate the issue.
An example embodiment of the present invention including an ability to predict the onset of an occlusion assumes the two pump architecture of
In the event blood components begin to deposit in the catheter connection line, the signature of the flush pump pressure begins to change with each successive cycle until the flow resistance becomes significant to the point it's considered a partial occlusion.
These two figures illustrate, and motivate the means for predicting the onset of either full or partial occlusion. The method first records an initial pressure deflection metric from the draw and infusion stages. Then for each cycle, the metric updates a filter that estimates the rate of change of flush pressure for the draw and infusion stages. By testing this rate of change against a threshold rate, the system is able to decide and alert the caretaker of an impending occlusion, and furthermore if the occlusion is specific to draw or infusion. Similarly, the initial blood pump pump-rate and the rate for each cycle during draw and infusion is recorded. The rate of change of the pump rate can then be determined from each cycle to another and evaluated against a threshold and used to corroborate the pressure information.
An example embodiment of the present invention can provide a similar implementation of the method described above using draw-infuse cycles that, rather than using pressure targeted draw and infuse stages, use constant flow targets. In this example, the blood pump pressure is not constant as occlusion resistance increases. In this example, since the blood pump flow is the independent variable, it is not used to predict, however the blood pump pressure rate of change (on a cycle by cycle basis) is the predicting variable. Furthermore, if the occlusion proceeds between the blood pump and the junction of the flush line, the expected behavior of the blood and flush pump pressures differ such that the onset of occlusion is predicted as well as its location (in the blood line rather than the catheter connection).
The expected trends depending on the type of blood access (pressure or flow based) and location are summarized below:
Predicting Occlusions in Phase Space.
The methods described above depend on time as a variable; however time and rates of change are not necessarily required to predict the onset of occlusion. Pairs of measurements that are compared independent of time are known as phase-plane or phase space analyses. With continuous, normal operation of the blood access controls, the phase-space relationship between variables (eg. Blood Pump Pressure—Flush Pump Pressure or Blood Pump Pressure—Blood Pump Flow) is repeatable on a cyclic basis. As an occlusion begins to manifest itself within the flow path, this phase plane signature begins to deviate, and by using an appropriate phase—plane envelope as a threshold, can be triggered to alert the operator of an impending occlusion.
Example Blood Access System Embodiments.
The methods, features, and elements described above in the context of some example blood access systems can also be implemented in other blood access systems, with appropriate modifications that those skilled in the art will appreciate based on descriptions herein. The terms “sensor” and “sensor system” as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to a device, component, or region of a device by which an analyte can be detected, quantified, or both.
The system shown in
The calibration solution 300 and the saline 302 are connected to the fluid delivery pumps 304 and are connected to a calibration solution supply tube 352 and a saline supply tube 354 respectively. The calibration solution supply tube 352 has a check valve 351 before connecting to the saline supply tube 354 at the fluid tube junction 353. The fluid tube junction connects to a sample tube junction 320. Although this embodiment shows two separate pumps, those skilled in the art will recognize that multichannel pumps are available that can pump multiple tubes. Additionally, saline 302 is attached through the fluid supply tubes 306 but those skilled in the art recognize that saline 302 is optional. Further, those skilled in the art will recognize that syringe pumps, gravity pumps, or other devices are available to deliver a fluid through an IV. The fluid delivery pumps 304 are well known in the art and are capable of volumetric control of one or more IV tubes thereby controlling the delivery rate of one or more drugs. The fluid delivery pumps 304 are controllable from an electronic controller 336. Further, the fluid delivery pumps 304 may communicate with the controller, including communicating delivery status information.
A bidirectional patient tube 322 connects the sample tube junction 320 to the patient 310. More specifically, the bidirectional patient tube 322 terminates in a catheter 311 which is intravenously placed in the patient 310. Therefore, the fluid delivery pump 304 may pump calibration solution 300 through the fluid supply tube 306 and the bidirectional patient tube 322 to be infused intravenously into the patient 310. This example embodiment also contains an analyzer 312 which communicates with the controller 336. Those skilled in the art will recognize that the controller 336 may be external to the analyzer 312 as shown in
When in use, the sample tube 318 extends from the sample tube junction 320 through the analyzer 312, with the clamp housing 316 set in the clamp housing holder 314 with a portion of the sample tube 318 extending around a peristaltic pump 324, occluding the sample tube 318. The peristaltic pump 324 is configured such that a platen arm 334 positions the sample tube 318 in compressioned contact with at least one roller 336 of the peristaltic pump 324. As the peristaltic pump 324 rotates the peristaltic pump 324 draws fluid through the sample tube 318 towards the analyzer, with the fluid being pushed out the blood dropper 328. The fluid supply tube 306, the bidirectional patient tube 322, and the sample tube 318 comprise the sample/supply set 308 shown in
In mode one, infuse mode, the controller 336 instructs the fluid delivery pump 304 to pump calibration solution 300 into the calibration solution supply tube 352. The fluid flows from the calibration solution 300 fluid supply, through the calibration solution supply tube 352 toward the sample tube junction 320. In the infuse mode, the peristaltic pump 324 of the analyzer 312 is rotating so as to pull calibration solution into the sensor 312. Therefore, the calibration solution 300 flowing through the calibration solution supply tube 352 flows through the sample tube junction 320 into tubing 318 and into sensor 312. The system has the ability to deliver both calibration fluid and saline to the patient depending upon the activation of pump 334. Further, the saline 302 and calibration solution 300 can be infused individually or simultaneously. The rate of infusion is set by the controller. When the controller or the user indicates it is time to take and analyze a new sample, mode two begins.
In mode two, sample mode, the example embodiment first flushes the system. The calibration solution pump 304 is first turned off and the saline pump activated. Those actions pump saline 302 through the saline tube 354, sample tube junction 320, the bidirectional flush tube 322, and the catheter 311, and to the patient 310. Once the flush path from the fluid tube junction 353 to the patient 310 is cleared of calibration solution, the peristaltic pump 324 is activated at a rate somewhat less than the rate of the saline pump 304. Then, the peristaltic pump 324 draws saline from the sample tube junction 320 through the sample tube 318, and out the blood dropper 328, cleaning the sample tube 318 of calibration solution. Since the saline pump 304 is pumping a rate faster than the peristaltic pump, a small quantify of saline is still being pumped to the patient 310. With the system now cleared of calibration solution, all pumps are stopped. After flushing the system, the system can inflate the pressure cuff 307, which is placed around an extremity and near the intravenous entry point of the patient 310. As the intravenous entry point is often the arm or hand, the pressure cuff may be placed on the upper arm. It is known in the art that the pressure of an inflated pressure cuff assists in the drawing of blood. With the cuff inflated, the preferred embodiment now takes a fluid sample, generally blood, from the patient 310 and draws the blood sample to the analyzer 312. In this mode, the fluid delivery pump 304 is not operational so no calibration solution is being pumped through the fluid supply tube 306. The peristaltic pump 324 rotates (clockwise as illustrated) and as each roller 336 contacts the sample tube 318, that roller 336 pushes fluid in the sample tube toward the blood dropper 328. The blood dropper 328 is positioned on a blood dropper arm 340, which moves the blood dropper 328 from a standby area to a position above a waste container 338. With the blood dropper 328 positioned over the waste container 338, fluid pushed through the sample tube 318 is deposited in the waster container 338. As the peristaltic pump 324 turns, a bolus of blood is pulled from the patient and up the bidirectional patient tube 322 toward the analyzer 312.
As the peristaltic pump 324 continues to operate, the bolus of blood reaches the clamp housing 316. The clamp housing 316 may contain an optical sensor to detect the leading edge of the blood sample. Since the volume of fluid in the sample tube 318 after the clamp housing 316 is known, and the volume moved by the peristaltic pump 324 is also defined, it can be calculated how much the peristaltic pump 324 must rotate until the blood has reached the blood dropper 328. Alternatively, if no optical sensor is used, the peristaltic pump 324 is rotated a sufficient number of times to bring the blood from the patient 310 to the blood dropper 328. After the blood sample is at the blood dropper 328, the peristaltic pump 324 stops. As a drop of blood may be left hanging from the blood dropper, the peristaltic pump 324 can be rotated in the opposite direction a small amount to draw the blood drop back into the blood dropper 328. The blood dropper arm 340 now moves to place the blood dropper 328 over the test area 330. As the sample mode ends the pressure cuff is deflated.
Mode three, the analyze mode, now begins. The analyzer 312 has a slide cassette 332 which is vertically positionable. The slide cassette 332 holds several slides 346, with each slide having at least one area that has a reagent which reacts with a substance that may be present in the patient's blood sample. The cassette 332 is positioned vertically such that a slide arm 326 contacts the desired slide 346 in the cassette 332. The slide arm 326 pushes the slide 346 and positions it into the test area 330. The peristaltic pump 324 is activated for a short time, pushing a small amount of blood from the blood dropper 328 into the test area 330. As noted previously analyzer 312 can be replaced by a variety of sensor methods to include indwelling biosensors and optical measurement sensors.
The therapeutic glucose solution 300 and the saline 302 are connected to the fluid delivery pumps 304 and are connected to a therapeutic glucose solution supply tube 352 and a saline supply tube 354 respectively. The therapeutic glucose solution supply tube 352 has a check valve 351 before connecting to the saline supply tube 354 at the fluid tube junction 353. The fluid tube junction connects to a sample tube junction 320. Although this embodiment shows two separate pumps, those skilled in the art will recognize that multichannel pumps are available that can pump multiple tubes. Additionally, saline 302 is attached through the fluid supply tubes 306 but those skilled in the art recognize that saline 302 is optional. Further, those skilled in the art will recognize that syringe pumps, gravity pumps, or other devices are available to deliver a fluid through an IV. The fluid delivery pumps 304 are well known in the art and are capable of volumetric control of one or more IV tubes thereby controlling the delivery rate of one or more drugs. The fluid delivery pumps 304 are controllable from an electronic controller 336. Further, the fluid delivery pumps 304 may communicate with the controller, including communicating delivery status information.
A bidirectional patient tube 322 connects the sample tube junction 320 to the patient 310. More specifically, the bidirectional patient tube 322 terminates in a catheter 311 which is intravenously placed in the patient 310. Therefore, the fluid delivery pump 304 may pump therapeutic glucose solution 300 through the fluid supply tube 306 and the bidirectional patient tube 322 to be infused intravenously into the patient 310. This example embodiment also contains an analyzer 312 which communicates with the controller 336. Those skilled in the art will recognize that the controller 336 may be external to the analyzer 312 as shown in
When in use, the sample tube 318 extends from the sample tube junction 320 through the analyzer 312, with the clamp housing 316 set in the clamp housing holder 314 with a portion of the sample tube 318 extending around a peristaltic pump 324, occluding the sample tube 318. The peristaltic pump 324 is configured such that a platen arm 334 positions the sample tube 318 in compressioned contact with at least one roller 336 of the peristaltic pump 324. As the peristaltic pump 324 rotates the peristaltic pump 324 draws fluid through the sample tube 318 towards the analyzer, with the fluid being pushed out the blood dropper 328.
The fluid supply tube 306, the bidirectional patient tube 322, and the sample tube 318 comprise the sample/supply set 308 shown in
In mode one, infuse mode, the controller 336 instructs the fluid delivery pump 304 to pump therapeutic glucose solution 300 into the therapeutic glucose solution supply tube 352. The fluid flows from the therapeutic glucose solution 300 fluid supply, through the therapeutic glucose solution supply tube 352 toward the sample tube junction 320. In the infuse mode, the peristaltic pump 324 of the analyzer 312 is not rotating and the platen arm 334 is pressed tightly against one or more of the rollers 336, thus occluding the sample tube 318. Therefore, the therapeutic glucose solution 300 flowing through the therapeutic glucose solution supply tube 352 flows through the sample tube junction 320 into the bidirectional patient tube 322 and via the catheter 311 into the patient 310. In a similar manner, the preferred embodiment may deliver saline 302 to the patient 310. Further, the saline 302 and therapeutic glucose solution 300 can be infused individually or simultaneously. The rate of infusion is set by the controller. When the controller or the user indicates it is time to take and analyze a new sample, mode two begins.
In mode two, sample mode, the system first flushes the system. The therapeutic glucose solution pump 304 is first turned off and the saline pump activated. Those actions pump saline 302 through the saline tube 354, sample tube junction 320, the bidirectional flush tube 322, and the catheter 311, and to the patient 310. Once the flush path from the fluid tube junction 353 to the patient 310 is cleared of therapeutic glucose solution, the peristaltic pump 324 is activated at a rate somewhat less than the rate of the saline pump 304. Then, the peristaltic pump 324 draws saline from the sample tube junction 320 through the sample tube 318, and out the blood dropper 328, cleaning the sample tube 318 of therapeutic glucose solution. Since the saline pump 304 is pumping a rate faster than the peristaltic pump, a small quantify of saline is still being pumped to the patient 310. With the system now cleared of therapeutic glucose solution, all pumps are stopped.
After flushing the system, the system may inflate the pressure cuff 307, which is placed around an extremity and near the intravenous entry point of the patient 310. As the intravenous entry point is often the arm or hand, the pressure cuff may be placed on the upper arm. It is known in the art that the pressure of an inflated pressure cuff assists in the drawing of blood. With the cuff inflated, the preferred embodiment now takes a fluid sample, generally blood, from the patient 310 and draws the blood sample to the analyzer 312. In this mode, the fluid delivery pump 304 is not operational so no therapeutic solution is being pumped through the fluid supply tube 306. The peristaltic pump 324 rotates (clockwise as illustrated) and as each roller 336 contacts the sample tube 318, that roller 336 pushes fluid in the sample tube toward the blood dropper 328. The blood dropper 328 is positioned on a blood dropper arm 340, which moves the blood dropper 328 from a standby area to a position above a waste container 338. With the blood dropper 328 positioned over the waste container 338, fluid pushed through the sample tube 318 is deposited in the waster container 338. As the peristaltic pump 324 turns, a bolus of blood is pulled from the patient and up the bidirectional patient tube 322 toward the analyzer 312.
As the peristaltic pump 324 continues to operate, the bolus of blood reaches the clamp housing 316. The clamp housing 316 may contain an optical sensor to detect the leading edge of the blood sample. Since the volume of fluid in the sample tube 318 after the clamp housing 316 is known, and the volume moved by the peristaltic pump 324 is also defined, it can be calculated how much the peristaltic pump 324 must rotate until the blood has reached the blood dropper 328. Alternatively, if no optical sensor is used, the peristaltic pump 324 is rotated a sufficient number of times to bring the blood from the patient 310 to the blood dropper 328. After the blood sample is at the blood dropper 328, the peristaltic pump 324 stops. As a drop of blood may be left hanging from the blood dropper, the peristaltic pump 324 can be rotated in the opposite direction a small amount to draw the blood drop back into the blood dropper 328. The blood dropper arm 340 now moves to place the blood dropper 328 over the test area 330. As the sample mode ends the pressure cuff is deflated.
Mode three, the analyze mode, now begins. The analyzer 312 has a slide cassette 332 which is vertically positionable. The slide cassette 332 holds several slides 346, with each slide having at least one area that has a reagent which reacts with a substance that may be present in the patient's blood sample. The cassette 332 is positioned vertically such that a slide arm 326 contacts the desired slide 346 in the cassette 332. The slide arm 326 pushes the slide 346 and positions it into the test area 330. The peristaltic pump 324 is activated for a short time, pushing a small amount of blood from the blood dropper 328 into the test area 330.
Automated blood analysis device 1 also comprises a series of tubes, including line 16, which are described in further detail below. In addition, automated blood analysis device 1 includes a first automated three-way stopcock 15 for controlling the flow inside line 16 and a second automated three-way stopcock 17 for controlling the flow of fluids to and from the external tubing and/or external devices. The operation of first stopcock 15 and second stopcock 17 is preferably fully automated and controlled by main unit 3. An automated sampling interface mechanism 18, described in further detail below, enables a blood sample to be brought automatically from line 16 to sensor 19 within sensor cassette 5. one of skill in the art will recognize that sensor cassette 5 can be replaced by a variety of glucose measurement means to include a biosensor in contact with the fluid and an optical measurement system. As further described in detail, automated blood analysis device 1 can work as a stand-alone device, or can be connected in parallel with external infusions (on the same venous line) or external pressure transducers (on the same arterial line) a location of connectivity is shown in
In the example embodiment of
When performing automated blood sampling and measurement of required blood analytes, main unit 3 directs second stopcock 17 to block incoming external infusions and to open the line from fluid bag 9 to patient 2. Once the external infusions are interrupted, pump 11 draws blood from patient 2. The blood is drawn along the tube until the remaining infusion volume and the initially diluted blood volume passes first stopcock 15. Main unit 3 calculates the required volume of blood to be withdrawn based on the diameter and length of the tubing and according to a programmable dead-space volume, which can be either pre-calibrated or user-defined. Optionally, a blood optical sensor 20 can be used to establish whether undiluted blood has reached the tube segment proximal to first stopcock 15. When undiluted blood reaches first stopcock 15, first stopcock 15 is repositioned to create an open line between patient 2 and sensor cassette 5. Blood is then pumped into line 16 via pump 13.
When undiluted blood reaches the tube segment proximal to sensor cassette 5, a blood sample is automatically taken inside sensor cassette 5 (by sampling interface mechanism 18) whereby a sensor 19 (from a plurality of sensors within sensor cassette 5) is placed into contact with the drawn blood sample. Sensor 19 is preferably, but not limited to, a single use sensor, and is used to measure patient blood analyte(s) and blood parameter(s). Sensor 19 is preferably a component of a manual test device, such as, but not limited to glucose test strips for measuring glucose levels. While the blood sample is analyzed, blood withdrawal from patient 2 is stopped, main unit 3 reverses the operation of pump 11, and first stopcock 15 is repositioned to infuse blood back into patient 2. The tubing components, including line 16, are then flushed by purging fluid from fluid bag 9. Blood and fluids from line 16 are stored in waste container 7, which is, for example, but not limited to a waste bag generally used for storage of biological disposals. Optionally, the remaining blood in line 16 can be infused back into patient 2 by reversing the direction of pump 13. After purging both line 16 and the line between fluid bag 9 and patient 2, main unit 3 redirects first stopcock 15 and second stopcock 17 to block both line 16 and the line between fluid bag 9 and patient 2 and reopen the line from the external infusion device, into patient 2.
Referring back to
The tubing and stopcocks/valve sets of the example embodiments can be implemented in various designs to support operational requirements. Optionally, the tubing includes filter lines to enable elimination of air embolism and particle infusion. Additionally, the tubing can optionally include a three-way stopcock that enables the user/clinician to manually draw blood samples for laboratory tests. In addition, three-way stopcock 17 may optionally include a plurality of stopcocks at its inlet, each controlling a separate external line. In another optional embodiment, the positions of stopcock 15 and stopcock 17 can be interchanged, thus placing stopcock 17 closer to the vascular access point in patient 2 than stopcock 15 or cassette 5. Automated blood analysis device 1 is connected to an insertion element, such as, but not limited to a catheter or a Venflon (not shown), inserted into a vein or artery to provide a flow path for fluid infusion and drawing of patient blood samples. Insertion into a vein or artery is performed according to existing clinical indications that are well known to those of ordinary skill in the art. This design avoids repeated insertions of needles or catheter structures into the patient as is commonly required with prior art blood chemistry monitoring techniques. Connection of the automated blood analysis device 1 to the catheter or venflon is made by standard means such as luer-lock connectors, as are known in the art. Optionally, the insertion element, catheter or venflon, can be part of the tubing of automated device for analyzing blood 1. In another example embodiment, the catheter may comprise a multi-lumen catheter wherein one of the lumens is used for automatically drawing the blood sample.
The terms “inserted” or “pre-inserted” as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to insertion of one thing into another thing. For example, a catheter can be inserted into a host's blood stream. In some embodiments, a catheter is “pre-inserted,” meaning inserted before another action is taken (e.g., insertion of a catheter into a host's blood stream prior to insertion of a sensor into the catheter). In some exemplary embodiments, a sensor is coupled to a pre-inserted catheter, namely, one that has been previously inserted (or pre-inserted) into the host's circulatory system.
Referring now to
In some embodiments, the catheter is inserted into the host's blood stream, such as into a vein or artery by any useful method known in the art. Generally, prior to and during insertion, the catheter is supported by a hollow needle or trochar (not shown). For example, the supported catheter can be inserted into a peripheral vein or artery, such as in the host's arm, leg, hand, or foot. Typically, the supporting needle is removed (e.g., pulled out of the connector) and the catheter is connected (e.g., via the connector 18) to IV tubing and a saline drip, for example. However, in one embodiment, the catheter is configured to operatively couple to medical equipment, such as but not limited to a sensor system of the preferred embodiments. Additionally and/or alternatively, the catheter can be configured to operatively couple to another medical device, such as a pressure transducer, for measurement of the host's blood pressure.
In some embodiments, the catheter and the analyte sensor are configured to indwell within the host's blood stream in vivo. An indwelling medical device, such as a catheter or implant, is disposed within a portion of the body for a period of time, from a few minutes or hours to a few days, months, or even years. In some embodiments, the catheter can indwell in a host's artery or vein for the length of a perioperative period (e.g., the entire hospital stay) or for shorter or longer periods. In some embodiments, the use of an indwelling catheter permits continuous access of an analyte sensor to a blood stream while simultaneously allowing continuous access to the host's blood stream for other purposes, for example, the administration of therapeutics (e.g., fluids, drugs, etc.), measurement of physiologic properties (e.g., blood pressure), fluid removal, and the like.
The function of the valves, pumps, actuators, drivers, motors (e.g., the centrifuge motor), etc. described below is controlled by one or more controllers (e.g., the fluid system controller 405, the optical system controller 413, etc.) The controllers can include software, computer memory, electrical and mechanical connections to the controlled components, etc. At the start of a measurement cycle, most lines, including a patient tube 512 (T1), an Hb sensor tube 528 (T4), an anticoagulant valve tube 534 (T3), and a sample cell 548 can be filled with saline that can be introduced into the system through the infusion tube 514 and the saline tube 516, and which can come from an infusion pump 518 and/or a saline bag 520. The infusion pump 518 and the saline bag 520 can be provided separately from the system 510. For example, a hospital can use existing saline bags and infusion pumps to interface with the described system. The infusion valve 521 can be open to allow saline to flow into the tube 512 (T1).
Before drawing a sample, the saline in part of the system 510 can be replaced with air. Thus, for example, the following valves can be closed: air valve 503 (PV0), the terg tank valve 559 (V7b), 566 (V3b), 523 (V0), 529 (V7a), and 563 (V2b). At the same time, the following valves can be open: valves 531 (V1a), 533 (V3a) and 577 (V4a). Simultaneously, a second pump 532 (pump #0) pumps air through system 510, pushing saline through tube 534 (T3) and sample cell 548 into a waste bladder 554.
Next, a sample can be drawn. With the valves 542 (PV1), 559 (V7b), and 561 (V4b) closed, a first pump 522 (pump #1) is actuated to draw sample fluid to be analyzed (e.g. blood) from a fluid source (e.g., a laboratory sample container, a living patient, etc.) up into the patient tube 512 (T1), through the tube past the two flanking portions of the open pinch-valve 523 (V0), through the first connector 524 (C1), into the looped tube 530, past the hemoglobin sensor 526 (Hb12), and into the Hb sensor tube 528 (T4). During this process, the valve 529 (V7a) and 523 (V0) are open to fluid flow, and the valves 531 (V1a), 533 (V3a), *42 (PV1), *59 (V7b), and 561 (V4b) can be closed and therefore block (or substantially block) fluid flow by pinching the tube.
Before drawing the sample, the tubes 512 (T1) and 528 (T4) are filled with saline and the hemoglobin (Hb) level is zero. The tubes that are filled with saline are in fluid communication with the sample source (e.g., the fluid source 402). The sample source can be the vessels of a living human or a pool of liquid in a laboratory sample container, for example. When the saline is drawn toward the first pump 522, fluid to be analyzed is also drawn into the system because of the suction forces in the closed fluid system. Thus, the first pump 522 draws a relatively continuous column of fluid that first comprises generally nondiluted saline, then a mixture of saline and sample fluid (e.g., blood), and then eventually nondiluted sample fluid. In the example illustrated here, the sample fluid is blood.
The hemoglobin sensor 526 (Hb12) detects the level of Hemoglobin in the sample fluid. As blood starts to arrive at the hemoglobin sensor 526 (Hb12), the hemoglobin level rises. A hemoglobin level can be selected, and the system can be pre-set to determine when that level is reached. A controller such as the fluid system controller 405 of
In some embodiments, when nondiluted blood is present at the first connector 524 (C1), a sample is mixed with an anticoagulant and is directed toward the sample cell 548. An amount of anticoagulant (e.g., heparin) can be introduced into the tube 534 (T3), and then the undiluted blood is mixed with the anticoagulant. A heparin vial 538 (e.g., an insertable vial provided independently by the user of the system 510) can be connected to a tube 540. An anticoagulant valve 541 (which can be a shuttle valve, for example) can be configured to connect to both the tube 540 and the anticoagulant valve tube 534 (T3). The valve can open the tube 540 to a suction force (e.g., created by the pump 532), allowing heparin to be drawn from the vial 538 into the valve 541. Then, the anticoagulant valve 541 can slide the heparin over into fluid communication with the anticoagulant valve tube 534 (T3). The anticoagulant valve 541 can then return to its previous position. Thus, heparin can be shuttled from the tube 540 into the anticoagulant valve tube 534 (T3) to provide a controlled amount of heparin into the tube 534 (T3).
With the valves 542 (PV1), 559 (V7b), 561 (V4b), 523 (V0), 531 (V1a), 566 (V3b), and 563 (V2b) closed, and the valves 529 (V7a) and 553 (V3a) open, first pump 522 (pump #1) pushes the sample from tube 528 (T4) into tube 534 (T3), where the sample mixes with the heparin injected by the anticoagulant valve 541 as it flows through the system 510. The sample continues to flow until a bubble sensor 535 (B S9) indicates the presences of the bubble. In some embodiments, the volume of tube 534 (T3) from connector 524 (C1) to bubble sensor 535 (BS9) is a known amount, and may be, for example, approximately 100 microliters.
When bubble sensor 535 (BS9) indicates the presence of a sample, the remainder of the sampled blood can be returned to its source (e.g., the patient veins or arteries). The first pump 522 (pump #1) pushes the blood out of the Hb sensor tube 528 (T4) and back to the patient by opening the valve 523 (V0), closing the valves 531 (V1a) and 533 (V3a), and keeping the valve 529 (V7a) open. The Hb sensor tube 528 (T4) is preferably flushed with approximately 2 mL of saline. This can be accomplished by closing the valve 529 (V7a), opening the valve 542 (PV1), drawing saline from the saline source 520 into the tube 544, closing the valve 542 (PV1), opening the valve 529 (V7a), and forcing the saline down the Hb sensor tube 528 (T4) with the pump 522. In some embodiments, less than two minutes elapse between the time that blood is drawn from the patient and the time that the blood is returned to the patient.
Following return of the unused patient blood sample, the sample is pushed up the anticoagulant valve tube 534 (T3), through the second connector 546 (C2), and into the sample cell 548, which can be located on the centrifuge rotor 550. This fluid movement is facilitated by the coordinated action (either pushing or drawing fluid) of the pump E22 (pump #1), the pump E32 (pump #0), and the various illustrated valves. Pump movement and valve position corresponding to each stage of fluid movement can be coordinated by one or multiple controllers, such as a fluid system controller.
After the unused sample is returned to the patient, the sample can be divided into separate slugs before being delivered into the sample cell 548. Thus, for example, valves 553 (V3a) and 531 (V1a) are opened, valves 523 (V0) and 529 (V7a) are closed, and the first pump 522 (pump #1) uses saline to push the sample towards sample cell 548. In some embodiments, the sample (for example 100 microliters) is divided into four “slugs” of sample, each separated by a small amount of air. As used herein, the term “slug” refers to a continuous column of fluid that can be relatively short. Slugs can be separated from one another by small amounts of air (or bubbles) that can be present at intervals in the tube. In some embodiments, the slugs are formed by injecting or drawing air into fluid in the first connector 546 (C2).
In some embodiments, when the leading edge of the sample reaches blood sensor 553 (BS14), a small amount of air (the first “bubble”) is injected at a connector 546 (C2), defining the first slug, which extends from the bubble sensor to the first bubble. In some embodiments, the valves 503 (PV0) and 559 (V7b) are closed, the valve 556 (V3b) is open, the pump 532 is actuated briefly to inject a first air bubble into the sample, and then valve 556 (V3b) is closed.
In some embodiments, the volume of the tube 534 (T3) from the connector 546 (C2) to the bubble sensor 552 (BS14) is less than the volume of tube 534 (T3) from the connector 524 (C1) to the bubble sensor 535 (BS9). Thus, for example and without limitation, the volume of the tube 534 (T3) from the connector 524 (C1) to the bubble sensor 535 (BS9) is approximately 100 .mu.L, and the volume of the tube 534 (T3) from the connector 546 (C2) to the bubble sensor 552 (BS14) is approximately 15 .mu.L. In some embodiments, four blood slugs are created. The first three blood slugs can have a volume of approximately 15 .mu.L and the fourth can have a volume of approximately 35 .mu.L.
A second slug can be prepared by opening the valves 553 (V3a) and 531 (V1a), closing the valves 523 (V0) and 529 (V7a), and operating the first pump 522 (pump #1) to push the first slug through a first sample cell holder interface tube 582 (N1), through the sample cell 548, through a second sample cell holder interface tube 584 (N2), and toward the waste bladder 554. When the first bubble reaches the bubble sensor 552 (BS14), the first pump 522 (pump #1) is stopped, and a second bubble is injected into the sample, as before. A third slug can be prepared in the same manner as the second (pushing the second bubble to bubble sensor 552 (BS14) and injecting a third bubble). After the injection of the third air bubble, the sample can be pushed through system 510 until the end of the sample is detected by bubble sensor 552 (BS14). The system can be designed such that when the end of the sample reaches this point, the last portion of the sample (a fourth slug) is within the sample cell 548, and the pump 522 can stop forcing the fluid column through the anticoagulant valve tube 534 (T3) so that the fourth slug remains within the sample cell 548. Thus, the first three blood slugs can serve to flush any residual saline out the sample cell 548. The three leading slugs can be deposited in the waste bladder 554 by passing through the tube F56 (T6) and past the tube-flanking portions of the open pinch valve 557 (V4a).
In some embodiments, the fourth blood slug is centrifuged for two minutes at 7200 RPM. Thus, for example, the sample cell holder interface tubes 582 (N1) and 584 (N2) disconnect the sample cell 548 from the tubes 534 (T3) and 562 (T7), permitting the centrifuge rotor 550 and the sample cell 548 to spin together. Spinning separates a sample (e.g., blood) into its components, isolates the plasma, and positions the plasma in the sample cell 548 for measurement. The centrifuge 550 can be stopped with the sample cell 548 in a beam of radiation (not shown) for analysis. The radiation, a detector, and logic can be used to analyze the a portion of the sample (e.g., the plasma) spectroscopically (e.g., for glucose, lactate, or other analyte concentration).
In some embodiments, portions of the system 510 that contain blood after the sample cell 548 has been provided with a sample are cleaned to prevent blood from clotting. Accordingly, the centrifuge rotor 550 can include two passageways for fluid that may be connected to the sample cell holder interface tubes 582 (N1) and 584 (N2). One passageway is sample cell 548, and a second passageway is a shunt 586. An embodiment of the shunt 586 is illustrated in more detail in
The shunt 586 can allow cleaner (e.g., tergazyme A) to flow through and clean the sample cell holder interface tubes without flowing through the sample cell 548. After the sample cell 548 is provided with a sample, the interface tubes 582 (N1) and 584 (N2) are disconnected from the sample cell 548, the centrifuge rotor 550 is rotated to align the shunt 586 with the interface tubes 582 (N1) and 584 (N2), and the interface tubes are connected with the shunt. With the shunt in place, the terg tank 559 is pressurized by the second pump 532 (pump #0) with valves 561 (V4b) and 563 (V2b) open and valves 557 (V4a) and 533 (V3a) closed to flush the cleaning solution back through the interface tubes 582 (N1) and 584 (N2) and into the waste bladder 554. Subsequently, saline can be drawn from the saline bag 520 for a saline flush. This flush pushes saline through the Hb sensor tube 528 (T4), the anticoagulant valve tube 534 (T3), the sample cell 548, and the waste tube 556 (T6). Thus, in some embodiments, the following valves are open for this flush: 529 (V7a), 533 (V3a), 557 (V4a), and the following valves are closed: 542 (PV1), 523 (V0), 531 (V1a), 566 (V3b), 563 (V2b), and 561 (V4b).
Following analysis, the second pump 532 (pump #0) flushes the sample cell 548 and sends the flushed contents to the waste bladder 554. This flush can be done with a cleaning solution from the terg tank 558. In some embodiments, the second pump 532 is in fluid communication with the terg tank tube 560 (T9) and the terg tank 558 because the terg tank valve 559 (V7b) is open. The second pump 532 forces cleaning solution from the terg tank 558 between the tube-flanking portions of the open pinch valve 561 and through the tube 562 (T7) when the valve 559 is open. The cleaning flush can pass through the sample cell 548, through the second connector 546, through the tube 564 (T5) and the open valve 563 (V2b), and into the waste bladder 554.
Subsequently, the first pump 522 (pump #1) can flush the cleaning solution out of the sample cell 548 using saline in drawn from the saline bag 520. This flush pushes saline through the Hb sensor tube 528 (T4), the anticoagulant valve tube 534 (T3), the sample cell 548, and the waste tube 556 (T6). Thus, in some embodiments, the following valves are open for this flush: 529 (V7a), 533 (V3a), 557 (V4a), and the following valves are closed: 542 (PV1), 523 (V0), 531 (V1a), 566 (V3b), 563 (V2b), and 561 (V4b).
When the fluid source is a living entity such as a patient, a low flow of saline (e.g., 1-5 mL/hr) is preferably moved through the patient tube 512 (T1) and into the patient to keep the patient's vessel open (e.g., to establish a keep vessel open, or “KVO” flow). This KVO flow can be temporarily interrupted when fluid is drawn into the fluid system 510. The source of this KVO flow can be the infusion pump 518, the third pump 568 (pump #3), or the first pump 522 (pump #1). In some embodiments, the infusion pump 518 can run continuously throughout the measurement cycle described above. This continuous flow can advantageously avoid any alarms that may be triggered if the infusion pump 518 senses that the flow has stopped or changed in some other way. In some embodiments, when the infusion valve 521 closes to allow pump 522 (pump #1) to withdraw fluid from a fluid source (e.g., a patient), the third pump 568 (pump #3) can withdraw fluid through the connector 570, thus allowing the infusion pump 518 to continue pumping normally as if the fluid path was not blocked by the infusion valve 521. If the measurement cycle is about two minutes long, this withdrawal by the third pump 568 can continue for approximately two minutes. Once the infusion valve 521 is open again, the third pump 568 (pump #3) can reverse and insert the saline back into the system at a low flow rate. Preferably, the time between measurement cycles is longer than the measurement cycle itself (e.g., longer than two minutes). Accordingly, the third pump 568 can insert fluid back into the system at a lower rate than it withdrew that fluid. This can help prevent an alarm by the infusion pump.
One of skill in the art can appreciate that the centrifuge and measurement process depicted in 550 can be replaced by other measurement methodologies to include indwelling biosensor technologies, optical measurement technologies that do not require centrifugation and in somatic strip methodologies were the sample is simply placed on the measurement system.
The present invention has been described in connection with various example embodiments. It will be understood that the above description is merely illustrative of the applications of the principles of the present invention, the scope of which is to be determined by the claims viewed in light of the specification. Other variants and modifications of the invention will be apparent to those of skill in the art.
This application claims the benefit of U.S. provisional application 61/044,004, filed Apr. 10, 2008, and of U.S. provisional application 60/991,373, filed Nov. 30, 2007; and of U.S. Provisional Application No. 60/991,447, filed Nov. 30, 2007; and of U.S. Provisional Application No. 60/992,037, filed Dec. 3, 2007; each of which is incorporated herein by reference.
| Number | Date | Country | |
|---|---|---|---|
| 61044004 | Apr 2008 | US | |
| 60991373 | Nov 2007 | US | |
| 60991447 | Nov 2007 | US | |
| 60992037 | Dec 2007 | US |
